Enalapril Maleate
Hyperhomocysteinemia
Fuling Central Hospital of Chongqing CityUNKNOWNPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hyperhomocysteinemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Folic Acid Shenzhen Ausa Pharmed Co.,Ltd | Phase 4 | BBB |
Folate Universidade Estadual de Londrina | Phase 4 | BB |
AMLODIPINE Shenzhen Ausa Pharmed Co.,Ltd | Phase 4 | BB |
PYRIDOXOL Center for Health Sciences, Serbia | Phase 3 | BB |
Test 4 Center for Health Sciences, Serbia | Phase 3 | BB |
Vibisone Georgetown University | N/A | D |
L-5-MTHF IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A | D |
Same molecule, other indications
Enalapril Maleate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →